The Pfizer Foundation Grants

The Pfizer Foundation Grants is sponsored by The Pfizer Foundation. The Pfizer Foundation provides funding and resources to organizations that expand and improve global health strategies, with a focus on access to quality health care and community involvement.

Competitive Grants Program | Pfizer Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Efforts to Improve Quality of Migraine Care Release Date: March 4, 2026 Partner: The Japanese Headache Society Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Internal Medicine Japan June 30, 2026 Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid) Release Date: March 10, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Rare Disease USA June 3, 2026 2026 Hemophilia Fellowship – United States Release Date: April 1, 2026 Review Process: Expert Review Panel View RFP (PDF) Fellowship Rare Disease All June 30, 2026 Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative Strategies Release Date: April 29, 2026 Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Oncology All July 1, 2026 Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice Release Date: April 30, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology USA June 11, 2026 Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding Disorders Release Date: May 12, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Rare Disease All July 1, 2026 Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways Release Date: May 13, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom July 1, 2026 Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach Release Date: May 14, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Inflammation & Immunology USA July 14, 2026 Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptoms Release Date: May 14, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland June 25, 2026 Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC Release Date: May 15, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology USA July 2, 2026 Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Pneumococcal Disease Prevention Release Date: April 11, 2012 Review Process: View RFP (PDF) Release Date: May 8, 2012 Review Process: View RFP (PDF) Release Date: June 28, 2012 Review Process: View RFP (PDF) Pharmacy Pneumococcal Disease Prevention Release Date: June 28, 2012 Review Process: View RFP (PDF) Release Date: July 2, 2012 Review Process: View RFP (PDF) Non-Small Cell Lung Cancer Release Date: July 10, 2012 Review Process: View RFP (PDF) Cardiovascular Risk in Rheumatoid Arthritis Release Date: July 25, 2012 Review Process: View RFP (PDF) Release Date: July 26, 2012 Review Process: View RFP (PDF) Adult Pneumococcal Disease Prevention Release Date: August 29, 2012 Review Process: View RFP (PDF) Prevention of Stroke in Women Release Date: September 13, 2012 Review Process: View RFP (PDF) Oncology Educational Needs Assessments Release Date: October 22, 2012 Review Process: View RFP (PDF) Release Date: November 1, 2012 Review Process: View RFP (PDF)